[1]
“SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent benefit across age and frailty, with no excess hypoglycaemia”, d, vol. 4, no. 15, pp. 28–29, Jul. 2026, Accessed: Jul. 28, 2026. [Online]. Available: https://thediabzen.com/index.php/d/article/view/57